Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-06-19
2002-08-20
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S550000
Reexamination Certificate
active
06436922
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to 5,11-dihydrodibenzo[b,e][1,4]oxazepine derivatives, stereoisomers thereof, pharmacologically acceptable salts thereof or hydrates thereof, which have a calcium channel blocking activity and are useful for the therapy and the treatment of the digestive tract abnormal moving function diseases, especially the intestinal diseases such as the irritable bowel syndrome as well as a pharmaceutical composition containing the same as an active ingredient.
BACKGROUND OF THE INVENTION
For example, European Patent No. 0404359A1 discloses that 5,11-dihydrodibenzo[b,e][1,4]thiazepine derivatives are useful as a calcium channel blocker having a selectivity for the gastrointestinal tract. Quinn, P. et al., Brit. J. Pharmacol. 1994, 112(Suppl.), Abst p573 and Wallis, R. M. et al., Brit. J. Pharmacol. 1994, 112(Suppl.), Abst p574 disclose that (S)-5-[1-[2-(Methoxyphenyl)ethyl]pyrrolidin-2-ylmethyl]-5,11-dihydrodibenzo[b,e][1,4]thiazepine maleate which is one of the above-mentioned derivatives has the same activity as mentioned above. However, the above-mentioned compounds are problematic in that they exhibit an anticholinergic activity which gives a side effect such as hydrodipsia, mydriasis or the like.
In recent years, as the social environment has become complicated, a lot of people have come to be under great stress, and there have been a large number of patients suffering from an irritable bowel syndrome of which main symptoms are abnormal bowel movement, abdominal pain and the like. To cope with such diseases, an anticholinergic agent, a laxative agent, an antidiarrheal drug, a drug for controlling intestinal function, a mucosa paralyzant, a drug for controlling an intestinal tract moving function, an agent of controlling an autonomic nerve, a herb medicine, an antianxiety agent, an antidepressant, a hypnotic agent, a neuroleptic agent and the like have been used so far. However, clinical effects of these agents are insufficient, and these agents are not necessarily satisfactory in view of the side effects. Accordingly, the development of a new type of a drug which is free of a side effect and which has an excellent activity of improving a digestive tract moving function has been in demand.
DISCLOSURE OF THE INVENTION
An object of the present invention is to provide a novel compound having an excellent activity of improving a digestive tract moving function.
Another object of the present invention is to provide a novel compound which is free of a side effect and which has an excellent activity of improving a digestive tract moving function.
Another object of the present invention is to provide a pharmaceutical composition containing said compound.
These and other objects of the present invention will be apparent from the following description and examples.
It has been considered that since a calcium channel blocker exhibits an activity of inhibiting contraction of a smooth muscle, it is effective for treating diseases caused by abnormal acceleration of contraction of the intestinal tract, for example, intestinal diseases such as an irritable bowel syndrome. In fact, it has been reported that a calcium channel blocker such as nicardipine, verapamil or the like is effective for treating an irritable bowel syndrome [Am. J. Gastroenterol., 80, 317 (1985), Gut., 28, 1609 (1987), J. Clin, Psychiatry., 48, 388 (1987), and Pharmacol. Ther., 60, 121 (1993)]. Actually, however, this calcium channel blocker is little applied clinically owing to its main effect on the heart blood vessel system. Under these circumstances, the present inventors have assiduously conducted investigations to develop a calcium channel blocker which exhibits a low toxicity, namely which gives no influence to the heart blood vessel system and which has a selectivity for the intestinal tract as an agent of treating the digestive tract abnormal moving function diseases, especially the intestinal diseases such as the irritable bowel syndrome. As a result, they have found that a compound represented by formula [I] gives a calcium channel antagonism selectively to the intestinal tract, and that it is effective as an agent of improving a digestive tract abnormal moving function which is almost free from side effects such as an anticholinergic activity, a decrease in the body temperature and the like. These findings have led to the completion of the present invention. That is, the present invention relates to 5,11-dihydrodibenzo[b,e][1,4]oxazepine derivatives represented by formula [I]:
wherein R
1
and R
2
are the same or different and each represents a hydrogen atom, a halogen atom, a cyano group, a hydroxy group or a lower alkoxy group, or R
1
and R
2
together form —O(CH
2
)nO— in which n is 1, 2 or 3, R
3
represents a hydrogen atom or hydroxy group, R
4
and R
5
are the same or different and each represents a hydrogen atom or hydroxy group, or R
4
and R
5
together form ═O group, stereoisomers thereof, pharmacologically acceptable salts thereof, or hydrates thereof as well as a pharmaceutical composition containing the same as an active ingredient.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
In formula [I], examples of the halogen atom of R
1
and R
2
include fluorine and chlorine atoms. Examples of the lower alkoxy group include an alkoxy group having 1 to 5 carbon atoms such as methoxy, ethoxy and n-propoxy groups. Examples of —O(CH
2
)
n
O— include methylenedioxy, ethylenedioxy and propylenedioxy groups. Among these, fluorine atom is preferable as the halogen atom, and an alkoxy group having 1 to 3 carbon atoms is preferable as the lower alkoxy group.
In the present invention, it is preferable that R
3
1
R
4
and R
5
in the formula [I] each be a hydrogen atom. In this connection, it is preferable that R
1
and R
2
in the formula [I] be the same or different and each represent a hydrogen atom, a halogen atom or a lower alkoxy group, provided that the both R
1
and R
2
do not represent a hydrogen atom at the same time. Furthermore, it is more preferable that R
1
represent a hydrogen atom, and R
2
represent a halogen atom or a lower alkoxy group. Among these, the most preferred are (R)-(+)-5,11-dihydro-5-[1-(4-methoxyphenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine having the following formula, pharmacologically acceptable salts thereof and hydrates thereof.
(R)-(+)-5,11-dihydro-5-[1-(4-fluorophenethyl)-2-pyrrolidinylmethyl]dibenzo[b,e][1,4]oxazepine, pharmacologically acceptable salts thereof and hydrates thereof are also the most preferable.
Examples of the pharmacologically acceptable salts of Compounds [I] in the present invention include mineral (inorganic) acid salts such as a hydrochloride, a hydrobromide, a sulfate and a phosphate; and organic acid salts such as an acetate, a lactate, a fumarate, a maleate, a malate, a tartrate, a citrate, an oxalate, an aspartate and a methanesulfonate. Among these, inorganic acid salt is preferred.
Compounds [I] of the present invention have one asymmetric carbon atom, and can include optical isomers. These optical isomers, mixtures thereof or racemic compounds thereof are included in Compounds [I] of the present invention. In this connection, the R form is preferred. Further, Compounds [I] and the pharmacologically acceptable salts thereof in the present invention may be present in the form of hydrates or solvates. Thus, these hydrates or solvates are also included in the present invention.
Compound [I] of the present invention can be produced as schematically shown below, for example.
wherein R
1
to R
5
are as defined above, and X represents a chlorine atom, a bromine atom or an iodine atom. In this respect, it is preferable that R
3
, R
4
and R
5
each represents a hydrogen atom.
Compound [I] of the present inv
Inoue Kimihiro
Kamisaki Toshiaki
Kawakami Yoshinari
Misumi Keiji
Moriguchi Masahiko
Ajinomoto Co. Inc.
Coleman Brenda
LandOfFree
5,11-dihydrobenzo[b,e][1,4]oxazepine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5,11-dihydrobenzo[b,e][1,4]oxazepine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5,11-dihydrobenzo[b,e][1,4]oxazepine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2960273